Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue

NCT01319916 | Completed Phase 1

• 1 other identifier: ATX-101-10-18
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

Open Label Study to Evaluate the Serum Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 into Abdominal Fat Tissue

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• Effects of ATX-101 on serum lipid and deoxycholate

  acute effects of ATX-101 on serum lipid and deoxycholate profile following subcutaneous administration into abdominal fat tissue.

Secondary Outcomes (1)

• Adipokine levels following subcutaneous administration of ATX-101

Interventions

ATX-101 DRUG

ATX-101 2mg/cm2

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Healthy, non-smoking males and nonpregnant, nonlactating females who are 18 to 65 years of age, inclusive, on Day 1A.
• \. Body mass index (BMI) of 18.5 to ≤ 30.0 at within 28 days before the dose of study material.
• \. Stable weight (e.g., approximately ± 10 lbs), in the judgment of the investigator, for at least 3 months before Day 1A.
• \. Sufficient abdominal tissue surface for which 50 injections spaced on 1 cm grid (4 cm x 9 cm square) can be safely administered into fat tissue.
• \. Fasting glucose within normal limits (i.e., 75-100 mg/dL) at within 28 days before the dose of study material.
• \. Fasting hemoglobin A1c within normal limits for the laboratory designated for this trial (e.g., 4 - 5.9%) at within 28 days before the dose of study material.
• \. Fasting triglycerides within normal limits for the laboratory designated for this trial (e.g., \< 150m/dL) at within 28 days before the dose of study material.
• \. Fasting cholesterol within normal limits for the laboratory designated for this trial (e.g., \< 200 mg/dL) at within 28 days before the dose of study material.
• \. Females must have a negative serum human chorionic gonadotropin (hCG) test result from a sample obtained within 28 days before the beginning of the confinement period and again after admission to the research facility for the confinement period, but before the dose of study material. Females must agree to practice adequate contraception, in the judgment of the investigator, during the course of the trial.
• \. Negative hepatitis B, hepatitis C, and HIV test results. 11. The subject is expected to comply with and understand the visit schedule and all of the protocol-specified tests and procedures.
• \. The subject is medically able to undergo the administration of study material as determined by clinical and laboratory evaluations obtained within 28 days before Day 1A for which the investigator identifies no clinically significant abnormality.
• \. Signed informed consent obtained before any study-specific procedure is conducted

You may not qualify if:

• \. History of any intervention (e.g., liposuction) or trauma associated with the abdominal area, which in the judgment of the investigator, may affect subject's safety or other evaluations of treatment.
• \. Subjects who, for any reason, are on active diet, calorie restriction, or attempting to lose weight.
• \. Blood donation of 500 mL or blood transfusion within 60 days before Day 1A, or plasma donation within 7 days before Day 1A.
• \. Diagnosis of lipodosis (e.g., Gaucher, Niemann-Pick, or Fabry disease) or other confounding metabolic diseases.
• \. History of hypertriglyceridemia (triglycerides \> 200 mg/dL), hypercholesterolemia (cholesterol \> 240 mg/dL), or hyperlipidemia.
• \. Use of statins (e.g., Vitorin, Lipitor, Lopid) or other lipid-lowering agent (e.g., nicotinic acid) within 28 days or five (5) half-lives, whichever is greater, before Day 1A.
• \. History of diabetes or screening results indicative of diabetes. 8. Use of antiglycemic agents at any time before screening. 9. Use of any medication that results in systemic exposure beginning during the screening period.
• \. Any medical condition (e.g., respiratory, cardiovascular, renal, hepatic, neurological disease, uncontrolled hypertension, thyroid dysfunction) that would interfere with laboratory or safety assessments, compromise the ability of the subject to undergo study procedures, or compromise the subject's ability to give informed consent.
• \. Treatment with oral anticoagulants (e.g., warfarin, heparin) within 10 days before Day 1A; anticipated need for agents with anticoagulative effects during the course of the trial.
• \. History of sensitivity to any components of the study material or topical anesthetics (e.g., lidocaine, benzocaine, novocaine).
• \. Previous enrollment into this trial or treatment with ATX-101 or agents containing deoxycholate.
• \. Treatment with an investigational agent within 28 days before Day 1A.

Sponsors & Collaborators

• Kythera Biopharmaceuticals: lead

Study Sites (1)

Robert Cooper, M.D. Cetero Research

Fargo, North Dakota, 58104, United States

Location

Study Officials

• Patricia Walker, MD, PhD

  Kythera Biopharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: March 18, 2011
• First Posted: March 22, 2011
• Study Start: December 1, 2010
• Primary Completion: January 1, 2011
• Study Completion: January 1, 2011
• Last Updated: March 22, 2011

Record last verified: 2011-03

Locations

US (1)